NeuroPace, Inc. (NPCE) News

NeuroPace, Inc. (NPCE): $8.17

0.39 (-4.56%)

POWR Rating

Component Grades

Momentum

F

Stability

C

Sentiment

Quality

C

Filter NPCE News Items

NPCE News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

NPCE News Highlights

  • NPCE's 30 day story count now stands at 2.
  • Over the past 2 days, the trend for NPCE's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • The most mentioned tickers in articles about NPCE are DEC, DRUG and VIEW.

Latest NPCE News From Around the Web

Below are the latest news stories about NEUROPACE INC that investors may wish to consider to help them evaluate NPCE as an investment opportunity.

NeuroPace Announces Early Completion of Patient Enrollment in NAUTILUS Pivotal Study

NAUTILUS is the first and only pivotal clinical study to evaluate neuromodulation therapy for treating drug refractory idiopathic generalized epilepsy Neuromodulation therapy is not currently indicated for patients with drug refractory generalized epilepsy If successful, NeuroPace’s RNS System would represent the first neuromodulation indication in idiopathic generalized epilepsy MOUNTAIN VIEW, Calif., Dec. 21, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial, growth-stage,

Yahoo | December 21, 2023

NeuroPace to Present at the 42nd Annual J.P. Morgan Healthcare Conference

MOUNTAIN VIEW, Calif., Dec. 19, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced that its management team will present at the 42nd Annual J.P. Morgan Healthcare Conference at 7:30am PT (10:30am ET) on Thursday, January 11, 2024, in San Francisco, CA as well as host investor meetings prior to and during the conference.The presentation will be accessible via live webc

Yahoo | December 19, 2023

NeuroPace to Leverage the Power of its RNS System’s Novel Data Collection, Brain Monitoring and Analysis Capabilities in Groundbreaking Collaboration

First of its kind, multi-year collaboration leverages RNS System’s data to track responses of implanted RNS System patients enrolled in a biotechnology company’s clinical trial In strategic data collaboration, clinical-stage biotechnology company to pay NeuroPace up to $3.7 million over two years to gain non-exclusive access to NeuroPace’s proprietary biomarker monitoring and data analysis capabilities for trial patients MOUNTAIN VIEW, Calif., Dec. 04, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (N

Yahoo | December 4, 2023

NeuroPace and the RNS System Showcased at the 77th American Epilepsy Society (AES) Annual Meeting

RNS System featured in over 50 Scientific Presentations and PostersMOUNTAIN VIEW, Calif., Dec. 01, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced that the Company will have a substantial presence at the 77th American Epilepsy Society Annual Meeting (AES 2023), to be held in Orlando, Florida and virtually from December 1-5, 2023. “The Society’s annual meeting is th

Yahoo | December 1, 2023

NeuroPace to Present at the Piper Sandler 35th Annual Healthcare Conference

MOUNTAIN VIEW, Calif., Nov. 21, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced will present at the Piper Sandler 35th Annual Healthcare Conference, taking place November 28-30 in New York, NY. Joel Becker, NeuroPace’s Chief Executive Officer, will provide a corporate presentation on Tuesday, November 28 at 2:30pm ET, and management will participate in one-on-one m

Yahoo | November 21, 2023

NeuroPace, Inc. (NASDAQ:NPCE) Q3 2023 Earnings Call Transcript

NeuroPace, Inc. (NASDAQ:NPCE) Q3 2023 Earnings Call Transcript November 6, 2023 NeuroPace, Inc. beats earnings expectations. Reported EPS is $-0.28, expectations were $-0.39. Operator: Ladies and gentlemen, greetings and welcome to the NeuroPace, Inc. Third Quarter 2023 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. It is now my pleasure […]

Yahoo | November 7, 2023

NeuroPace Inc (NPCE) Reports 47% YoY Revenue Growth in Q3 2023, Raises Full Year Revenue Guidance

Reduced cash burn and increased revenue guidance highlight the company's strong financial performance

Yahoo | November 6, 2023

NeuroPace Reports Third Quarter 2023 Financial Results and Increases Full Year 2023 Revenue Guidance

Third quarter 2023 revenue of $16.4 million, an increase of 47% year-over-year Full-year revenue guidance increased to $62.5-$63.5 million, up from $59-$61 million Cash burn reduced to $2.2 million in the third quarter of 2023, relative to $4 million in the second quarter of 2023 MOUNTAIN VIEW, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today reported financi

Yahoo | November 6, 2023

NeuroPace, Inc.'s (NASDAQ:NPCE) top owners are private equity firms with 54% stake, while 21% is held by institutions

Key Insights Significant control over NeuroPace by private equity firms implies that the general public has more power...

Yahoo | November 2, 2023

12 Best Performing NASDAQ Stocks in 2023

In this piece, we will take a look at the 12 best performing NASDAQ stocks in 2023. If you want to skip our introduction to the NASDAQ’s performance this year and the broader stock market, then read 5 Best Performing NASDAQ Stocks in 2023. The NASDAQ has been one of the best performing stock indexes […]

Yahoo | October 26, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!